Table 4 Results of CGH analysis, FISH, SSCP analysis, and immunohistochemistry in malignant PCC
Samples | Patients | Characteristics | CGH 17p | FISH p53 | SSCP | IH |
|---|---|---|---|---|---|---|
1 | 1 | F/47 sp/adr/u | • | • | ○ | ○ |
2 | 2 | F/65 sp/adr/u | • | • | ○ | ○ |
3 | 3 | F/70 sp/adr/u | • | • | ○ | ○ |
4 | 4 | F/56 sp/adr/u | • | — | ○ | — |
5 | meta | — | — | ○ | ○ | |
6 | 5 | F/30 sp/ea/u | — | • | — | ○ |
7 | Meta intercost I | ○ | — | ○ | • | |
8 | Meta intercost II | • | • | ○ | — | |
9 | 6 | M/70 sp/adr/u | — | — | — | ○ |
10 | Meta LN | • | • | ○ | — | |
11 | 7 | F/53 sp/ea/u | — | — | — | ○ |
12 | Meta | ○ | — | ○ | ○ | |
13 | 8 | F/27 sp/adr/u | ○○ | ○○ | ○ | ○ |
14 | 9 | F/32 sp/adr/u | ○ | — | ○ | — |
15 | Meta LN I | ○ | ○ | ○ | ○ | |
16 | Meta LN II | ○ | — | ○ | — | |
17 | 10 | M/32 sp/ea/u | ○ | ○ | ○ | ○ |
18 | 11 | M/36 sp/adr/u | ○ | ○ | ○ | ○ |
19 | Meta LN | — | — | ○ | ○ | |
20 | 12 | F/23 sp/adr/u | ○ | ○ | ○ | — |
21 | Meta bone | — | — | ○ | • | |
22 | 13 | F/62 sp/adr/u | ○ | ○ | ○ | ○ |
23 | 14 | M/42 sp/adr/u | ○ | — | ○ | — |
24 | 15 | M/42 sp/adr/u | — | — | ○ | — |
25 | 16 | F/39 sp/adr/u | — | — | ○ | ○ |
26 | /49 meta LN | ○ | — | ○ | — | |
27 | 17 | F/45 sp/adr/u | ○ | — | ○ | — |
28 | Meta LN | — | ○ | — | — | |
29 | 18 | F/32 sp/adr/u | — | — | ○ | — |
30 | Meta liver | ○ | — | ○ | — |